Cough Management Wellness App for Refractory or Unexplained Chronic Cough

Launched by HYFE INC · Jul 9, 2025

Keywords

ClinConnect Summary

This clinical trial is testing a new smartphone app called CoughPro to help adults who have a long-lasting cough that hasn’t improved with usual treatments and doesn’t have a clear cause. The study wants to see if using the app’s Cough Management program for four weeks can reduce how often people cough, make their cough less intense, and improve how they feel overall. The app teaches techniques based on cough-suppression therapy, which helps people learn ways to control their cough better.

To join, participants need to be 21 years or older, have had a mostly dry cough lasting at least eight weeks, and have had a chest X-ray or CT scan to rule out other problems. They should also have tried standard cough treatments without much success. During the study, participants will wear a special smartwatch that tracks their coughs for six weeks, complete lessons and practice exercises on the app for four weeks, and fill out simple questionnaires about their cough and quality of life before and after the program. At the end, they’ll have a short interview, return the watch, and receive a voucher as a thank-you. This study is currently recruiting adults who meet these criteria.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age 21 or older.
• • Currently suffering from a cough that started at least 8 weeks ago that is largely unproductive (i.e., at least 50% of the time the cough produces zero mucus that needs to be spit out or swallowed).
• • Normal chest X-ray or chest CT scan at some point that was prescribed specifically for their cough.
• • At least one physician visit for cough with standard-of-care therapy but inadequate symptom relief.
• • Stability of treatment: willing to avoid new cough treatments during study or report changes if they occur.
• • Ability to comply: willing/able to wear the watch daily for the required duration of study and to complete all required questionnaires.
• • Informed consent: understanding of the study procedures and agreement to comply with protocol.
• Exclusion Criteria:
• • Recent upper respiratory infection (past 4 weeks).
• • History of hemoptysis (coughing up blood) since onset of the current cough.
• • Current smoker (incl. vaping) of any substance.
• • ≥10 consecutive pack-years smoking history within \<10 years prior to screening.
• • Diagnosed with a chronic lung condition (COPD, emphysema, lung cancer, IPF, chronic bronchitis, asthma). Note: Suspected asthma without confirmed diagnosis or benefit from asthma therapy is not an exclusion.
• • Current or past head/neck cancer.
• • Difficulty swallowing.
• • On ACE inhibitors, such as Benzapril (Lotensin), Captopril (Capoten), Enalapril/Enalaprilat (Vasotec oral and injectable), Fosinopril (Monopril), Lisinopril (Zestril and Prinivil), Moexipril (Univasc), Perindopril (Aceon), Quinapril (Accupril), Ramipril (Altace), and Trandolapril (Mavik)
• • Prior treatment for cough by a speech-language pathologist.
• • Living with another individual with a frequent cough that would interfere with monitoring.
• • Participation in any cough intervention study within 30 days or 5 half-lives of the intervention.
• • Major scheduled surgery during the study period.